Management of drug interactions with Nirmatrelvir/Ritonavir (Paxlovid).

Management of Drug Interactions With Nirmatrelvir/Ritonavir (Paxlovid®): Resource for Clinicians – Infectious Diseases Society of America

Commentary: IDSA offers guidance on managing drug interactions with nirmatrelvir/ritonavir – ACP Internist

Related:

Paxlovid’s failure as a preventative measure raises questions, but doctors still back it as a therapeutic – STAT

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

Covid-19: What is the evidence for the antiviral Paxlovid? – The BMJ

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator – World Health Organization

A living WHO guideline on drugs for covid-19 – The BMJ

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions – Annals of Internal Medicine

The COVID-19 Treatment Guidelines Panel’s Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications – NIH COVID-19 Treatment Guidelines Panel